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Decamer Oligodeoxyribonucleotide Duplex and
a Quinoxaline ([MeCys3, MeCys7]TANDEM)
Drug Duplex Complex
Robert Powers,1 Richard K. Olsen,2 and David G. Gorenstein1
1. Department of Chemistry, Purdue University, West Lafayette, Indiana 47907
2. Department of Chemistry, Utah State University, Logan, Utah 84322

Abstract
Assignment of the 1H and 31P NMR spectra of a decamer oligodeoxyribonucleotide duplex,
d(CCCGATCGGG), and its quinoxaline ([MeCys3, MeCys7]TANDEM) drug duplex complex has
been made by two-dimensional 1H-1H and heteronuclear 31P-1H correlated spectroscopy. The 31P
chemical shifts of this 10 base pair oligonucleotide follow the general observation that the more internal the phosphate is located within the oligonucleotide sequence, the more upfield the 31P resonance occurs. While the 31P chemical shifts show sequence-specific variations, they also do not
generally follow the Calladine “rules” previously demonstrated. 31P NMR also provides a convenient
monitor of the phosphate ester backbone conformational changes upon binding of the drug to the
duplex. Although the quinoxaline drug, [MeCys3, MeCys7]TANDEM, is generally expected to bind
to duplex DNA by bis-intercalation, only small 31P chemical shift changes are observed upon binding
the drug to duplex d(CCCGATCGGG). Additionally, only small perturbations in the 1H NMR and
UV spectra are observed upon binding the drug to the decamer, although association of the drug
stabilizes the duplex form relative to the other states. These results are consistent with a nonintercalative mode of association of the drug. Modeling and molecular mechanics energy minimization
demonstrate that a novel structure in which the two quinoxaline rings of the drug binds in the minor
groove of the duplex is possible.
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Introduction
It is now widely appreciated that duplex DNA can exist in a number of different conformations (1). Significant conformational differences can exist globally along the entire double helix, as in the A, B, C, and Z forms of DNA (1). In addition, local conformational
heterogeneity in the deoxyribose phosphate backbone has been most recently noted in the
form of sequence-specific variations (2–4) or as the result of drug (1) or protein binding
(5,6) to local regions of the DNA. While X-ray crystallography has provided much of our
understanding of these DNA structural variations, increasingly, high resolution NMR has
also begun to provide detailed three-dimensional structural information on duplex oligonucleotides (7–16) and drug duplex complexes.
Bis-intercalators
There is a limited amount of structural information on the bis-intercalators–DNA binding
drugs that possess two covalently linked intercalating rings. Studies have centered primarily around acridine dimers, ethidium dimers, ditercalinium, and more recently echinomycin, triostin A, and their derivatives (17–24). The latter two are members of the quinoxaline
class of naturally occurring antibiotic, antimicrobial, and antitumor drugs (25–27). Quinoxalines are divided into two subclasses: quinomycins (such as echinomycin) and the triostins, which are differentiated by the type of sulfur bonds across the cyclic depsipeptide
(fig. 1). The triostins have a simple disulphide bridge while the quinomycins have a thioacetal cross-bridge.
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Figure 1. (A) Structures of bis-intercalators, Trisotin A, [MeCys3, MeCys7]TANDEM, and
TANDEM. (B) Stereo view of [MeCys3, MeCys7]TANDEM based upon the X-ray structure
of TANDEM.

They are C-shaped (fig. 1B) with a pair of parallel quinoxaline rings perpendicular to
the cyclic depsipeptide (28–31).
The initial interest in bis-intercalators was in designing drugs with higher DNA binding
affinity and sequence specificity. The rationale behind this research was the existence of a
good correlation between DNA binding affinity and the drug’s efficacy against L 1210 murine leukemia in female DBA/2 mice and the growth of P-388 cells in culture and in DBA/2
mice (32,33). The bis-intercalators with a higher DNA binding affinity demonstrated a
higher antitumor activity. The effect of bis-intercalation was also examined by the ability
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of these compounds to inhibit E. coli DNA polymerase I (21). Bis-intercalating compounds
inhibited this process more efficiently than did the corresponding mono-intercalators.
The identification of the bis-intercalation mode of binding was based primarily on their
ability to unwind closed circular DNA and lengthen the DNA helix. This process was monitored by the change in the sedimentation coefficient and viscosity of the DNA with the
addition of drug. The results were referenced to the ethidium monomer which is a known
mono-intercalator with a defined unwinding angle of 26°. All of the studied drugs demonstrated a relative unwinding angle of approximately twice that of the ethidium monomer
(17,18,26,27,34). In addition to viscometric studies, electron microscopy was used to measure
the lengthening of the DNA helix by the presence of the drug (20). All of the bis-intercalators
lengthened the DNA helix approximately twice the distance of ethidium bromide at the
same drug/base-pair ratio. The presence of intercalation was also monitored by the typical
bathochromic and hypochromic shifts of UV spectra for intercalators (26,35). More recently, an X-ray crystal structure of a triostin A–d(CGTACG)2 complex clearly shows both
quinoxaline chromophores intercalated between the GC base pairs with the cyclic depsipeptide situated in the minor groove forming hydrogen bonds between the alanine residues NH and the guanosine N-3 (36). NMR studies of ethidium dimer–poly(dA-dT)2,
diacridines-d(AT)5-d(AT)5, diacridine-d(CGCG)2, and diacridine–calf thymus DNA and
echinomycin-d(ACGT)2 complexes have supported the bis-intercalation of these drugs by
observing upfield shifts of imino, and aromatic protons affected by the nuclear shielding
of the stacked chromophore and observing drug-DNA NMR data consistent with bisintercalation. In particular, nuclear Overhauser effects were observed between the ditercalinium’s chromophore protons and the H1′, H2″, and base protons of the GC base pair in
the ditercalinium-d(CGCG)2 complex (23) as well as a fairly complete set of intermolecular
NOEs establishing the solution structure of an echinomycin-d(ACGT)2 complex (24). The
later study represents the only NMR study on the DNA binding of the quinoxaline family
of bis-intercalators. The present study deals with the analysis of a triostin A analog
([MeCys3, MeCys7]TANDEM) binding to the duplex decamer d(CCCGATCGGG)2. The
study involves UV, 31P, and 1H NMR analysis of the [MeCys 3, MeCys7]TANDEM ·
d(CCCGATCGGG)2 drug duplex complex. The results indicate that the binding of
[MeCys3, MeCys7]TANDEM to the decamer is not by intercalation but appears to bind in
a nonspecific manner to the minor groove of the DNA.
Experimental Methods
Materials
The self-complementary decamer d(CCCGATCGGG) was synthesized by a manual modification of the solid phase phosphite triester method (using 10 μmole of the starting nucleoside
derivatized support) as previously described (12,37–39). The purity of the decamer was
verified by chromatography on an anion-exchange column, a silica column coated with
crosslinked polyethylene imine (40). The decamer NMR sample was prepared by dissolving ca. 500 OD units in 0.4 ml 100 mM phosphate buffer (D20) pH 7.0 (uncorrected pH
meter reading), 100 mM KCl, 1 mM EDTA, 1 mM sodium azide.
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The decamer was labeled with 17O and 18O to assist in the assignment of the 31P spectrum. The 17O/18O label was incorporated at the appropriate step in the DNA sequence by
using 17O/18O water during the oxidation step of the DNA synthesis as previously described (12,37).
The [MeCys3, MeCys7]TANDEM sample was prepared as previously described (41,42).
A decamer · [MeCys3, MeCys7]TANDEM (0.8:1) complex was made by adding 6.94 mg (12
μmol) [MeCys3, MeCys7]TANDEM to a 8.25 μmol sample of decamer in ca. 1 mL of water.
Approximately 20% acetonitrile was added to the mixture to bring [MeCys3, MeCys7]TANDEM into solution. The sample was shaken vigorously for 24 hours, followed by centrifugation to remove undissolved drug and the supernatant roto-evaporated to remove most
of the acetonitrile. The sample was then repeatedly dissolved in double distilled water,
centrifuged, and the supernatant lyophilized to remove the remaining acetonitrile. A small
amount of acetonitrile remained in the golden orange color solution. The sample was
treated with Chelex-100 resin again for the NMR studies (the UV spectrum did not change
upon Chelex treatment). The concentration of decamer and duplex in solution for both the
UV (see below) and NMR studies was estimated from the UV spectrum of the drug complex utilizing the extinction coefficients of the duplex and drug measured separately. They
were consistent with an ca. 0.8:1 ratio of drug/duplex (estimated error ± 10%).
UV spectra were collected on a CARY 210 UV spectrophotometer with a temperaturecontrolled sample holder. A 1 cm pathlength cell was used for the UV spectra. All UV
samples were a 1,000 fold dilution of the corresponding NMR sample, resulting in an OD
of approximately 0.5 at λmax of 260 nm. The decamer and decamer · [MeCys3, MeCys7]TANDEM samples were aqueous solutions with a KCl concentration of 100 mM and 100 mM
phosphate buffer pH 7.0. The decamer UV melting curves were measured at two concentrations (6.0 and 3.0 μM) and a range of salt concentrations (0–400 mM KCl). For the UV
titration study, the 1 ml decamer · [MeCys3, MeCys7]TANDEM complex was titrated with
0.13 O.D. 1 μl aliquots of decamer. The resulting spectra were observed against either a
blank solution or the decamer · [MeCys3, MeCys7]TANDEM.
NMR spectra of the decamer and decamer · [MeCys3, MeCys7]TANDEM samples were
performed on either a Nicolet NTC-470, 470 MHz NMR instrument or a Varian XL-200A,
200 MHz NMR spectrometer. The 1H NMR spectra, the 2D NOESY and COSY spectra for
both the decamer and decamer · [MeCys3, MeCys7]TANDEM samples were run on the Nicolet NTC-470. The 1H spectra were referenced to H20 at 4.76 ppm. A spectral window of
5000 Hz was used for all the NTC-470 experiments except for the temperature dependence
of the imino protons in which a spectral window of 10000 Hz was used. For the onedimensional experiments, 8K data points were collected. For the two-dimensional experiments 256 FIDs by 2K data sets were collected. The HDO solvent signal was saturated with
a decoupler pulse of 55 dB and pulse width of 30 μs. In addition, a noise generator centered
at the water resonance was used for all 1H NMR experiments except for the imino melting
profile experiments. The decoupler pulse was off during acquisition.
The 31P ID NMR spectra, the 31P melting profiles, the 1H/31P correlation COLOC (PAC)
spectra, and the 1H/31P heteronuclear 2D J-resolved spectrum were run on the XL-200A.
All experiments were run in either 99.998% D2O or 85%H2O/15%D2O. Typical 31P 1D NMR
parameters were as follows: sweep width 172 Hz; acquisition time 2.98 s; block size 1K
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zero filled to 16K; pulse width 7.0 μs; spectra were resolution enhanced with a combination
of positive exponential and Gaussian apodization functions; the number of acquisitions
was between 2000 and 3000. The 31P spectra were referenced to trimethyl phosphate (TMP)
at 0.000 ppm, which is 3.456 ppm downfield of 85% phosphoric acid.
The temperature dependence of the imino proton 1H spectrum was measured with a
modified one-dimensional water suppression sequence (WS1D; 43). The WS1D sequence
is:
RD-HSP-90-D-90-HSP-90-D-D-90-HSP-acq
where:
RD = recovery delay
HSP = homospoil pulse and recovery
D = delay optimized for imino protons.
The water suppression technique employs a spin-echo sequence to specifically subtract
out the HDO resonance. The above sequence contains four phase-cycled 90° pulses separated by either a homospoil pulse along the z and y axis or a delay optimized for the resonances of interest, which will rotate by 90° or 270° relative to the stationary HDO resonance.
The 90° pulse used was dependent on temperature and ranged from 20 μs to 32 μs. The
homospoil pulse was 2.0 ms with a recovery period of 200 μs. A delay of 180 μs corresponded to the difference in the imino and HDO resonances. A 2.0 s recovery delay was
used and the experiment was run with the sample nonspinning. Spectra were recorded
from 5 to 50°C at 5° intervals based on the NTC-470 thermocouple reading. Temperatures
were calibrated by using a methanol thermometer for temperatures up to 40°C.
The 1H chemical shifts were referenced to the 4.76 ppm HDO signal. All imino peak
integrations were referenced to the most downfield proton at 50°C, which was set to a
value of one proton. The decamer sample was run at both a 100 mM and 400 mM KCl
concentrations.
Absolute value 1H/1H COSY was taken of the decamer sample. The pure-absorption
phase COSY spectra of the drug-duplex complex were acquired. The spectra were acquired
with a sweep width of 5000 Hz. Approximately 320 transients were taken for each of the
256 FIDs with 2K data points of resolution. A 90° pulse of 14.6–15 μs and a recycle delay
of 2.2 s (absolute value spectra) or 3.5 s (pure absorption phase spectra) were used. For
both experiments, the initial t1 value was 100 μs and it was increased by 100 μs intervals.
The data was processed with 2K of zero filling in both the t1 and t2 dimension. A skewed
sign bell apodization function was used in the t2 dimension. The t1 dimension was processed with either magnitude calculation and an exponential apodization function with
line broadening of 10 Hz for the absolute value spectra or a skewed sign bell apodization
function for the pure absorption phase spectra.
Two-dimensional NOESY were acquired in the phase-sensitive mode using the TPPI
(44) phase-cycling scheme. The spectra were acquired with 2048 points in the t2 (acquisition) dimension with 1024 t1 increments. The mixing times (τm) ranged from 50 to 700 ms
for the decamer sample (200 and 400 ms mixing times were used for the decamer · [MeCys3,
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MeCys7]TANDEM complex). The recovery delay time for the decamer was 2.2 s. 90° pulses
ranged from 11–14 μs for the decamer sample. The recovery delay for the decamer ·
[MeCys3, MeCys7]TANDEM sample was 2.2 s for 200 ms mixing time and 3.5 s for 400 ms
mixing time. 90° pulses ranged from 14–15 μs for the decamer · [MeCys3, N-MeCys7]TANDEM sample. The experiment was run with the sample nonspinning to minimize t1 noise.
For spectra recorded in 85%H2O/15%D2O, the H2O signal was irradiated during the mixing
time and the delay between scans. A homospoil pulse of 20 ms with a recovery time of 20
ms was applied just prior to the first 90° pulse.
The resulting data was processed using Dennis Hare’s FTNMR program, V4.5 or V4.7.
The data was processed with zero filling to 2K in both t2 and t1 dimensions. An exponential
line broadening of 1 Hz was used to apodize the data in the t2 dimension. A trapezoidal
apodization function was used for all the TPPI NOESY mixing times when the crosspeak
volumes were measured using the FTNMR program. The 400 ms TPPI NOESY was
apodized with a Gaussian multiplication in both t1 and t2 dimension when the resulting
spectrum was used strictly for the assignment of the proton spectrum.
The NOE crosspeak volumes were measured with FTNMR. The volumes were measured with either a constant J value of 1 or one optimized by the program (V4.7), ranging
from 1 to 3 depending on the size of the NOE crosspeak. The J value defined the width of
the ellipse used to approximate the crosspeak. The calculated distances utilizing either approaches were similar.
Although volumes were measured for a complete set of mixing times (50–700 ms) the
volumes for a single 200 ms TPPI NOESY were used to measure the intra and inter proton
distances from the observed NOE crosspeaks. The internal ruler for measuring the distances from the observed volumes was the H5-H6 NOE of C3. This resolved NOE was
assigned a value of 2.45 Å. The volume of a crosspeak, and its corresponding distance, was
not measured if a significant amount of crosspeak overlap existed.
A 31P/1H Pure Absorption Phase Constant Time (PAC) version of the Kessler-Griesinger
Long-Range Heteronuclear Correlation (COLOC) experiment (45) was conducted on the
decamer and the decamer · [MeCys3, MeCys7]TANDEM complex (46,47). The preacquisition delay was 2 s, the constant delay was 0.051 s, and the refocusing delay was 0.035 s. A
first order phase correction of 12,075° was used in the ω1 dimension. The PAC spectra were
acquired with a sweep width of 122.8 Hz in the t2 dimension and 641.9 Hz in the t1 dimension. The experiments were collected with 400–600 transients for each of the 64 FIDs with
256 data points of resolution. A 90° pulse of 7.5 μs for phosphorus and 80 μs for protons
was used. The data was processed with 1K zero filling in the t1 dimension and 512 zero
filling in the t2 dimension. A Gaussian apodization was applied in both the t1 and t2 dimension to give resolution enhancement.
The Bax-Freeman Selective 2D-J Resolved Long-Range Correlation experiment with a Dante
sequence for the selective 180° pulse (48) was performed on the decamer and the decamerTANDEM complex to correlate the 31P chemical shift with the phosphorus-H3′ coupling
constant. A Dante pulse chain consisted of 20 pulses of an approximate length of 9° (total
of 180°). The 9° pulse (8 μs) consisted of 0.4 μs of dead time. In addition, the pulses were
separated by a delay of 2 μs. The selective 2D-J long-range correlation experiment was
acquired with a sweep width of 50 Hz in the t1 dimension and 503.6 Hz in the t2 dimension.
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A 90° phosphorus pulse width of 7.5 μs and a 8.8 μs proton pulse width and a recycle delay
of 1.5 s was used. The experiment was collected with 1100–1600 transients for each of the
32 FIDs with 448 data points in t1. A t1 value of 0.l s was used. The data was processed with
1K zero filling in both the t2 and t1 dimension with a Gaussian apodization function to give
resolution enhancement in both dimensions.
The observed three-bond coupling constant is used with a proton-phosphorus Karplus
relationship to measure the H3′-C3′-O-P torsional angle θ from which we have calculated
the C4′-C3′-O-P torsional angle ε (= θ – 240°). The equation J = 15.3cos2(θ) – 6.lcos(θ) + 1.6
was used (48,49).
The 1D31P spectra were collected with a sweep width of 1000 Hz, 2Kdata points with
16K zero filling. A 90° pulse width of 7.5 μs, recycle delay of 1 s and either 256 or 512
transients were used to collect the spectrum. The data was processed with a Gaussian apodization function to give resolution enhancement. The temperatures of the 1H-decoupled 31P
NMR samples were corrected for decoupler heating of the sample. The 31P “thermometer”
consisted of a sample of phosphoric acid and trimethyl phosphate as previously described
(50). Note that even with WALTZ decoupling we find that decoupler heating can raise the
temperature of the sample by as much as 4°C.
NOESY Distance Constrained Molecular Mechanics Calculations of Duplex and Molecular Mechanics Calculations of Duplex · Drug Complex
The molecular mechanics/dynamics program AMBER (51) was used to initially generate
an idealized Arnott B-DNA decamer duplex structure (52). NOESY distance constraints
were incorporated into the AMBER potential energy function through addition of a flat
well potential (see Results). The model-built structure with 122 NOESY distance constraints were then energy refined until a rms gradient of 0.l kcal/mol-Å was achieved or
until the change in energy was less than 1.0 × 10–7 kcal/mol for successive steps.
The molecular mechanics program (AMBER) was also used to generate a molecular mechanics minimized structure for the decamer · [MeCys3, MeCys7]TANDEM complex. The
decamer structure in the complex was based upon the NOE constrained and minimized
structure of the free decamer. The [Met Cys3, Met Cys7] TANDEM structure was derived
from the X-ray structure coordinates of TANDEM (28,29). The difference between TANDEM and [Met Cys3, Met Cys7]TANDEM is the N-methyl group on each of the L-cysteines.
Charges for the serine quinoxaline and subfragment N-Met Cys of TANDEM were calculated using AM1 (53) with coordinates obtained from the X-ray structure of TANDEM.
After both the decamer and [MeCys3, MeCys7]TANDEM were minimized with AMBER,
[MeCys3, MeCys7]TANDEM was docked onto the NOESY distance-constrained, energyminimized decamer duplex using MIDAS (54). After docking [MeCys3, MeCys7]TANDEM
onto the decamer with MIDAS, the complex was energy minimized with the AMBER program.
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Results
Assignments of 31P Signals of Decamer Oligonucleotide Duplex
The 31P spectrum for the decamer
dCCCGATCGGG
dGGGCTAGCCC
1
is shown in figure 2.

Figure 2. 31P NMR spectra of decamer (bottom). Examples of site-specific 17O and 18O labeling of two of the phosphates of the decamer at positions C2pC3 (17O) and G4pA5 (18O)
(middle) and at positions G8pG (17O) and T6pC7 (18O) (top) are shown.

The decamer’s 31P signals were assigned by both a 2D pure absorption phase constant
time (PAC) heteronuclear correlation NMR (46,55) and 17O/18O labeling methodologies
(12).
As shown in figure 3 the PAC spectrum contains a pair of crosspeaks between the phosphorus resonance and either an H3′/H4′ pair or an H3′/H5′ pair—the proton signals had
been previously assigned by the 2D 1H/1H spectra (see below). Assignment of the 31P signal
of the ith phosphate was achieved through connectivities with both the 3′H(i) and 4′H (i + 1)
or 5′H(i + l)/5″H(i + 1) deoxyribose protons (39,56). Although the 5′H(i + 1) and 5″H(i + 1)
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protons overlap with the 4′ protons, the intensities for the 31P-5′H and 5″H PAC crosspeaks
generally appear to be weaker than the 4′H crosspeaks. These pairs of protons from the
PAC spectrum were then matched to appropriate pairs from the TPPI NOESY spectrum to
complete the assignment of the 31P spectrum.

Figure 3. Two-dimensional 31P-1H PAC heteronuclear correlation NMR spectrum of duplex decamer at 200 MHz (1H). The 1D decoupled 31P NMR spectrum is shown along one
axis and the H3′, H4′, and H5′5″ region of the proton spectrum is shown along the second
axis.

There existed some ambiguities in the assignments because of the similarity in chemical
shifts of a number of the H3′ protons and the ambiguities in the assignments of H4′, H5′,
and H5″ in several of the residues. Surprisingly, we observe some crosspeaks to both H4′,
H5′ and H5″ for several residues, in contrast to our earlier PAC spectra with a tetradecamer
in which only 3′ and 4′ crosspeaks were observed (46). The assignments of the 31P signals
of some of the phosphates of the decamer 1 were verified by the 17O/18O labeling methodology. We can readily introduce both 17O and 18O labels into the phosphoryl groups by
replacing the I2/H217 O in the oxidation step of the intermediate phosphite triester by I2/H217 O
and H218 O (12,37). In an earlier study on a tetramer oligonucleotide (37), our laboratory had
demonstrated that all three phosphate signals could be assigned by synthesizing the oligonucleotide with 17O, 18O, and 16O (unlabeled) in each of the three different phosphate
positions. Later studies on longer oligonucleotides (12,15,57–63) relied on single, regiospecific 17O labeling of the oligonucleotides, which, of course, requires separate n-1 syntheses
for each of the n phosphate positions of the oligonucleotide and is thus more time consuming. By simultaneously incorporating a single mono-17O phosphoryl and a separate mono18O phosphoryl labeled oligonucleotide (two specific phosphates are labeled along the
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strand), we can simultaneously identify the 31P signals of two phosphate diester signals
(assuming we can resolve the effect of the 17O and 18O label on the 31P signals). The quadrupolar 17O nucleus (generally ca. 40% enriched) broadens the 31P signal of the directly
attached phosphorus to such an extent that only the high-resolution signal of the remaining 60% nonquadrupolar broadened phosphate at the labeled site is observed (37,59,61).
Thus a decrease in intensity is observed for the phosphate signal labeled with 17O.
We can also identify the phosphate diester attached to the 18O label because of an isotope
effect on the 31P chemical shifts (37). The 18O isotope affects the 31P resonances by inducing
a small upfield isotope shift of 0.01–0.02 ppm. Therefore, if resolution is good enough, the
presence of the upfield isotope shifted peak in the 31P spectrum indicates the 18O labeled
phosphorus.
In this way six different 17O/18O double labeled decamer samples with a different disubstituted 17O/18O-phosphoryl group allows identification of two specific 31P signal and the
full series of dilabeled oligonucleotides gives the assignment of the entire 31P NMR spectrum.
Figure 2 shows representative 31P spectra of unlabeled and 17O/18O double-labeled
decamer. As can be seen in figure 2B/C, a decrease in intensity of a single resonance and a
resonance with an associated upfield shifted peak is observed. Most of the resonances can
clearly be distinguished, each integrating for one phosphorus resonance. Note that there
are slight chemical shift changes of some of the resonances attributed to small differences
in sample concentration, solvent, and temperature. The resonance of the 17O-labeled phosphate is observed as a reduced intensity peak in figures 2B/C and the 18O-labeled phosphorus resonance as an upfield shifted signal to the remaining unlabeled phosphate signal.
(The H217 O sample also contains both H216 O and H218 O; see Experimental.) This can be seen
in figures 2B and C where the 18O-labeled phosphate 31P signal is shifted slightly upfield
relative to the remaining 16O phosphorus resonance (37).
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Table I. P-31 Chemical Shifts and P-H3′ Coupling Constants for Duplex (CCCGATCGGG)
Base

P-3l(ppm)a

18.5°C
J(P-H3′) Hz

30°C
J(P-H3′) Hz

50°C
J(P-H3′) Hz

80°C
J(P-H3′) Hz

–3.974

3.8

4.0

5.2

6.6

–3.974

3.8

5.0

5.2

6.6

–3.736

5.0

5.2

6.6

7.0

–4.066

5.8/2.6

5.8

5.2

6.6

–4.321

2.2

3.4

2.6

5.8

–4.199

2.6

3.2

4.0

5.8

–4.072

5.8/2.6

5.8

5.2

6.6

–3.709

5.0

5.2

5.0

6.2

–3.914

6.0

5.0

5.2

7.0

C1
p
C2
p
C3
p
G4
p
A5
p
T6
p
C7
p
G8
p
G9
p
G10
a. P-31 chemical shifts referenced to trimethyl phosphate (0.000 ppm).

The individual 31P chemical shifts of the decamer duplex phosphorus signals (referenced to trimethyl phosphate, 0 ppm) are tabulated in table I and plotted vs. sequence in
figure 4.

Figure 4. Plot of 31P chemical shift (--O--) vs. phosphate position along the 5′-3′ strand for
duplex decamer. Also shown is a plot of calculated helix twist sum, tg, derived from calculated Σ1 sum function and equation [1]{tg = 35.6 + 2.1Σ1) vs. phosphate position (--□--).
The tg vs. sequence plot has been scaled to reflect the 31P chemical shift variations.
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As shown in figure 4 (and better illustrated in figure 5) there exists a strong correlation
between 31P chemical shifts of complementary residues of the decamer. Figure 5 compares
31P chemical shifts for complementary positions for the decamer duplex sequence, where
the solid line connects 31P chemical shifts for phosphate positions starting at the 5′ end and
proceeding in the 3′ direction, and the dashed line represents 31P chemical shifts for the
complementary 3′-5′ strand.

Figure 5. 31P chemical shift pattern comparison of complementary phosphate positions of
decamer. Solid lines: 5′-3′ direction; dashed lines: complementary 3′-5′’ direction.

Note that because of the palindromic symmetry of the oligonucleotide, the corresponding phosphates on opposite strands that are related by the two-fold dyad axis of symmetry
are chemically and hence magnetically equivalent. However, the “complementary” phosphates (phosphates opposite each other on complementary strands) are chemically and
magnetically nonequivalent. As previously noted (63), the 31P chemical shifts at complementary phosphate positions generally follow the same pattern in both strands of the duplex regardless of base sequence or position, suggesting that the phosphate geometry (see
below) is nearly the same in complementary positions along both strands.
Positional and Sequence-Specific Variation of 31P Chemical Shifts and Backbone
Torsional Angles
As mentioned above, one factor that will affect 31P chemical shifts is the degree of conformational constraint imposed by the duplex geometry (58,59,63,64). Note that the 31P chemical shift of phosphates 3 through 8 (fig. 4) move upfield the more interior the phosphate.
Base pairs closer to the ends of the duplex are less constrained to the stacked, base-paired
geometry. This “fraying” at the ends imparts greater conformational flexibility to the deoxyribose phosphate backbone, and thus phosphates at the ends of the duplex will tend to
adopt more of a mixture of g-, g– and t,g– conformations. Interior phosphates are more constrained to the polymer P-O g–, g– conformation.

13

POWERS ET AL., JOURNAL OF BIOMOLECULAR STRUCTURE AND DYNAMICS 7 (1989)

This “positional” 31P chemical shift effect is apparently superimposed on a sequencespecific effect (12,15,58,59,63). The minor groove clash steps (pyrimidine-purine base steps)
have been generally associated with a relatively downfield 31P chemical shift. However as
can be seen from the 31P chemical shift pattern shown in figure 4, the minor groove clash
steps at phosphate positions 3 and 7 appear to follow the positional effect. The relative
upfield shift of phosphates 1, 2, and 9 are presumably attributed to the sequence-specific
effect.
As discussed in more detail below, two of the most important parameters controlling
31P chemical shifts in phosphate esters are the P-O torsional angles (in nucleic acids the PO5′ (α) and P-O3′ (ζ) torsional angles (65,66) and the C-O5′ (β) and C-O3′ (ε) torsional angles) ( 67,68), although the P-O torsional angle may be more important. Using the selective
2D-J resolved long-range correlation experiment, we can measure the three-bond H3′-C3′O-P coupling constant (listed in table I) for each of the phosphates in the decamer (48,63).
The 2D spectra at selected temperatures are shown in figure 6.
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Figure 6. 2D-J resolved long-range correlation spectrum of decamer. The 1D decoupled
31P NMR spectrum is also shown along one axis and the H3′ coupled doublets are shown
along the second dimension (A) 18.5°, (B) 30°, (C) 50°, and (D) 80°.
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Figure 6, continued

Combined with a proton-phosphorus Karplus relationship (see Experimental Section)
we can determine the H3′-C3′-O-P torsional angle θ from which we have calculated the
C4′-C3′-O-P torsional angle ε. Up to four different torsional angles (0–360°) may be derived
from the same coupling constant, and we assume that the torsional angle ε closest to the
crystallographically observed value of ca. = –169° ± 25° (1) is the correct value. As shown
by Dickerson (3,4) there is a strong correlation (R = –0.92) between torsional angles ζ and ε
in the crystal structures of a dodecamer (ζ may be calculated from the relationship (3,4) ζ
= –317 – 1.23ε). Thus, assuming this correlation of ζ and ε exists for other duplex structures
in solution as well, and from the measured coupling constants, we can calculate both
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C4′-C3′-O3′-P(ε) and C3′-O3′-P-05′ (ζ) torsional angles. A plot of the variation of both ζ
(and ε) vs. 31P chemical shifts for the decamer sequence is shown in figure 7.

Figure 7. Comparison of 31P chemical shifts and P-O3′ ester torsional angle ζ and C-O3′
torsional angle ε for the decamer (O). ζ torsional angle calculated from the JH3′-P coupling
constants derived from figure 6, the calculated ε torsional angle from the Karplus relationship, and the correlation between ε and ζ (ζ = –317 – 1.23ε; note that there is a typographical error in the 96 paper).

The correlation coefficient between ζ (or ε) and 31P chemical shifts varies from –0.69 (at
ambient temperature) to –0.89 (at 50°C; the negative sign indicates that an increase in ε
results in a decrease in the 31P chemical shift). We have also confirmed that JH3′-P coupling
constants and 31P chemical shifts are strongly correlated for several other oligonucleotide
duplexes (62,63).
The data of figure 7 supports our hypothesis that the positional-specific and sequencespecific variation in 31P chemical shifts is largely attributable to variations in the helical
parameters and the backbone torsional angles (at least for ζ and ε). Unwinding or winding
the double helix changes the backbone α and ζ torsional angles, and these backbone
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changes presumably are responsible for the variations in the 31P chemical shifts of oligonucleotides.
The 31P NMR spectrum of the [MeCys3, MeCys7]TANDEM · decamer complex is very similar
to that of the decamer alone (spectrum not shown). Binding of an intercalating drug unwinds the duplex (1) and causes a downfield shift of the 31P signal (64,69). This unwinding
and lengthening of the deoxyribose phosphate backbone allows the drug to insert with a
base-to-base separation of 6.7 Å to accommodate the intercalated drug. This is apparently
accomplished by the phosphate switching from the normal B-DNA conformation (“BI”) in
which both P-O torsional angles ζ and α are in the g– conformation to the “BII” conformation (ζ = t, α = g–). The 31P signal of a phosphate in a t, g– BII conformation is predicted to
be ~1–1.5 ppm downfield from the g–, g– phosphate in the BI conformation ( 64,70), and we
expect to observe a large downfield shift of the 31P signal upon binding of a drug to DNA
by intercalation. Note that none of the phosphates in the [MeCys3, MeCys7]TANDEM ·
decamer complex is shifted significantly downfield relative to the decamer phosphate signals. This is strong support for the binding of the drug to the duplex by a nonintercalative
mechanism. The 2D-heteronuclear correlated and J resolved long-range correlation spectra
of the [MeCys3, MeCys7]TANDEM · decamer duplex complex (fig. 8 and 9) demonstrate
that binding of the drug produces some selective changes in the backbone torsional angles
of the duplex. Note specifically the reduction in the 31P-1H three-bond coupling constant
(from 5.4 to 2.0 Hz) of one of the most downfield of the 3lP signals.

Figure 8. Two-dimensional 31P-1H PAC heteronuclear correlation NMR spectrum of
[MeCys3, MeCys7]TANDEM · decamer duplex complex at 200 MHz (1H). The 1D decoupled 31P NMR spectrum is shown along one axis and the H3′, H4′, and H5′5″ region of the
proton spectrum is shown along the second axis.
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Figure 9. 2D-J resolved long-range correlation spectrum of [MeCys3, MeCys7]TANDEM ·
decamer duplex complex. The 1D decoupled 31P NMR spectrum is also shown along one
axis and the H3′ couplex doublets are shown along the second dimension. (A) 18.5°, (B)
30°, (C) 50°, and (D) 80°.
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Figure 9, continued

Proton NMR of Decamer Duplex
The sequence-specific assignment methodology (9, 10,12–14, 16) was used to identify the
proton NMR signals of the decamer. The two-dimensional NOESY and COSY spectra of
DNA contain definitive regions of proton chemical shifts. These regions correspond to the
aromatic base (H8/H6) region, the sugar H1′ and base H5 region, the sugar H2′/H2″ region
and the sugar H3′, H4′ and H5′/H5″ region (see fig. 10 for the NOESY spectrum of the
decamer duplex; the COSY spectrum is not shown—all spectra not shown are available
upon request from the authors). In a typical B-DNA conformation, the distance between a
sugar H1′ proton and its base proton and the (N-1) base proton to the 5′ end are within the
ca. 5 Å NOE limit (71). Thus, the base proton’s diagonal peak will have two corresponding

20

POWERS ET AL., JOURNAL OF BIOMOLECULAR STRUCTURE AND DYNAMICS 7 (1989)

NOE crosspeaks, except for the 5′ end base which will have only an NOE to its own H1′
sugar proton. This allows for a sequential assignment of the H1′ sugar protons and the
base protons down the DNA backbone. The usual starting point is at the 5′ end base since
it has only one corresponding NOE crosspeak. The next base in the sequence will have an
NOE which will line up with the 5′ end (N-1) base’s lone NOE (H1′-H8/H6 inter-residue
NOE) and its own H1′-H8/H6 intra-residue NOE. The sequential assignment continues
down the DNA backbone through a series of inter and intra H1′-H8/H6 NOEs (fig. l0B).

Figure 10. (A) Pure absorption phase 1H/1H NOESY NMR spectrum of duplex decamer,
at 470 MHz. (B) Region labeled A is expanded in 10B. The sequential assignment of the
base and deoxyribose H1′ protons is diagrammed.
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Figure 10. continued

Additional NOEs are seen, based on typical B-DNA structure, between H5 and H6, H1′
and H3′, H1′ and H2′/H2″, base protons and H2′/H2″, base protons and (N-1) H2′/H2″ to
the 5′end, H4′ and H5′/H5″, H3′ and H4′, H2′and H2″. All the additional protons can be
assigned after the H1′ and base protons have been assigned based on the previous list of
NOE connectivities. These additional NOEs allow for a secondary path if ambiguities arise
in the H1′ to H8/H6 sequential assignment or allow for redundancy in the assignments.
The base to H2′/H2″ region contains four crosspeaks, except for the 5′-end base. The intraresidue base to H2′/H2″ crosspeaks can be identified by comparing them with the crosspeaks in the H1′ to H2′/H2″ region. Similar to the H1′ to base region, a sequential walk can
be made down the DNA backbone from intra-base to H2′/H2″ NOEs to inter-base to
H2′/H2″ NOEs. In essence, it is possible to walk around the entire NOESY spectrum to
complete the assignments. Connectivities can be made from the Hl′ to H8/H6 region to the
H8/H6 to H2′/H2″ region to the H1′ to H2′/H2″ region to the H1′ to H3′ region and back to
the H1′ to H8/H6 region. This allows for redundancy checking and the presence of internal
consistency.
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This was the primary method of assigning the proton spectrum of the decamer. The
major obstacle in assigning the decamer was the large overlap in the H1′ to base region
(fig. l0B). The assignment of the 5′ end base by the presence of only one NOE was ambiguous. The sequential assignment began with the two highly resolved base resonances, one
upfield and one downfield. The downfield resonance was assigned to A5 and the upfield
resonance was assigned to T6. This was based on the normal distribution of chemical shifts
of the base protons and the presence of a sequential connectivity between these two resonances. The remainder of the bases corresponded to either guanosine or cytosine. The cytosine base protons were assigned from the COSY spectrum (not shown). The COSY
spectrum contains crosspeaks for the cytosine’s J-coupled H5 and H6 protons. The COSY
spectrum contains four crosspeaks in the base to H1′/H5 region corresponding to the four
cytosines in the sequence. These same crosspeaks are observed as NOEs in the TPPI NOESY spectrum, which allows for the identification of the cytosine H6 protons and by default the guanosine H8 protons. The sequential assignments of the guanosines and the
cytosines were then obtained by walking through the H1′ to base region starting from both
the A5 resonance and proceeding in the 5′ direction and from the T6 resonance and proceeding in the 3′ direction. The assignments were verified by comparison to the baseH2′/H2″ NOE region connectivities and by following the path around the spectrum: baseH1′ NOE’s to H1′-H2′/H2″ NOE’s to base-H2′/H2″ NOEs and back to base-H1′ NOE’s. The
H3′, H4′, and H5′/H5″ protons were assigned from the direct NOE’s between H1′-H3′ and
from spin diffusion of the H1′ protons to H4′ and H5′/H5″ and from spin diffusion from
the base protons to the H4′ and H5′/H5″ protons (observed in the NOESY spectra taken at
long mixing times). The H3′, H4′, and H5′/H5″ protons are also distinguished by their relative chemical shifts in the order H3′ > H4′ > H5′/H5″.
As discussed above the PAC spectra (fig. 3) correlates the 31P chemical shifts to the H3′,
H4′, and H5′/H5″ proton chemical shifts through scalar coupling. Because some of the 31P
assignments were independently made by oxygen labeling of the phosphates (and hence
some of the coupled protons could also be assigned) the PAC experiment provided confirmation of the NOESY 1H assignments. The H5′ and H5″ protons were not stereospecifically
assigned. The H2′/H2″ protons were stereospecifically assigned by their relative NOE intensity. In B-DNA, the H1′-H2′ crosspeak is always stronger than the H1′-H2″ crosspeak.
The T6 methyl group was assigned from the thymidine H6 base proton to the methyl group
COSY and NOESY crosspeaks. An additional NOESY crosspeak to the thymidine methyl
group is seen from the A5 H8 base proton. The A5 H2 proton is assigned by default from
the remaining peak in the aromatic region of the one dimensional proton spectrum. The
proton chemical shifts of the decamer duplex are compiled in table II.
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Table II. Proton Chemical Shift Assignments for Duplex
PACa,b/NOESYa,c
Base

H6/H8

H5

H1′

H2′/H2″

H3′

H4′

H5′/H5″

CH3

H2

C1

7.64

5.73

5.79

2.08/2.42

4.89/4.90

4.54

4.11/4.01

—

—

C2

7.55

5.57

5.90

2.10/2.37

4.77/4.77

4.54

4.12/3.99

—

—

C3

7.38

5.57

5.40

1.96/2.30

4.77/4.76

—

4.20/4.03

—

—

G4

7.85

—

5.57

2.67/2.76

4.95/4:91

4.30

4.04/3.97

—

—

A5

8.12

—

6.18

2.56/2.87

4.93/4.94

4.40

4.18/4.09

—

7.69

T6

7.07

—

5.82

1.94/2.36

4.77/4.77

—

4.10/4.04

1.27

—

C7

7.31

5.59

5.59

1.85/2.24

4.95/4.95

4.55

4.15/4.03

—

—

G8

7.76

—

5.38

2.58/2.58

4.88/4.88

4.22

4.04/4.02

—

—

G9

7.62

—

5.99

2.39/2.27

4.76/4.89

4.30

4.11/4.04

—

—

G10

7.64

—

5.55

2.08/2.38

/4.90

4.54

4.11/4.01

—

—

a. Proton chemical shifts referenced to HDO at 4.76 ppm.
b. Chemical shifts assigned from the P-31/H-1 2D PAC spectrum.
c. Chemical shifts assigned from the H-1/H-1 NOESY spectrum.

The decamer-drug proton spectrum was assigned by comparing the two-dimensional TPPI
NOESY spectrum of the decamer sample to the decamer · [MeCys3, MeCys7]TANDEM
spectrum (fig. 11).
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Figure 11. (A) Pure absorption phase 1H-1H NOESY NMR spectrum of duplex decamer ·
[MeCys3, MeCys7)TANDEM complex (0.8:1), at 470 MHz. (B) Region labeled A is expanded in 11B. The sequential assignment of the base and deoxyribose H1′ protons is
diagrammed.
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Figure 11, continued

The two spectra were basically identical. There were only minor chemical shift changes
in the decamer-drug complex (on the average of ± 0.03 ppm) and no decamer to [MeCys3,
MeCys7]TANDEM inter-residue NOEs were observed. [MeCys3, MeCys7]TANDEM intramolecular NOEs were observed between the C-alpha and C-beta protons of the cyclic depsipeptide. These crosspeaks overlapped greatly, and their assignment was not pursued
further.
The assignment of the decamer’s imino protons was based on relative chemical shifts and
the melting profiles (69,72–75). There are ten imino protons in the sequence, but because
of the palindromic nature of the sequence half of the protons are degenerate (fig. 12A).
The imino region of the decamer’s proton spectrum (400 mM KCl) contained only three
resonances. These resonances integrate (low to high field) for a ratio of 1:2:2 at 5°C. The
imino protons of AT base pairs are invariably downfield from the imino protons of GC
base pairs. Since the ratio of AT base pairs to GC base pairs in the decamer is one to four
and the most downfield resonance integrates for one proton, the most downfield resonance
was assigned to the AT base pair.
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Figure 12. (A) Proton NMR spectrum of the imino proton region of the decamer duplex
at indicated temperatures. (B) Proton NMR spectrum of the imino proton region of the
decamer · [MeCys3, MeCys7)TANDEM complex at indicated temperatures.

It is possible to utilize the melting of the imino proton signals to discriminate between
the interior and terminal base pairs. The imino protons are quite labile and exchange with
water, resulting in a decrease in intensity and increase in linewidth of the imino proton
resonance with temperature. An increase in the exchange rate of an imino proton is associated with transient breaking of the imino proton hydrogen bond and is generally reflective of a decrease in the stability of the base pair. The two remaining unassigned imino
resonances are associated with the four GC base pairs and each resonance has a distinct
melting temperature. The most up field resonance has a Tm of 25°C (fig. 12B). The remaining resonance has a Tm of 30°C. Because terminal base pairs generally melt (or undergo
“fraying”) at lower temperatures than interior base pairs—especially if the base pairs are
of the same type—the most upfield resonance was assigned to the two terminal GC imino
protons. By default, this leads the assignment of the middle imino resonance to the two
internal GC base pairs.
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Melting Curves
The UV melting curve of the decamer at low salt and DNA concentrations is shown in figure
13A. The 31P chemical shift melting profile of the decamer is shown in figure 13B. The temperature dependence of the 31P chemical shifts were followed by their relative position in the
spectrum. It was assumed that no dramatic chemical shift changes occurred over the 5° intervals which could have resulted in relative positional exchange of any of the resonances.

Figure 13, continued on next page
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Figure 13. (A) Temperature dependence of UV absorbance at 260 nm of decamer (0) and
decamer · [MeCys3, MeCys7]TANDEM (0.8:1) complex (□) at 100 mM KCl. (B) Temperature dependence of the 31P chemical shifts of the decamer. Phosphate positions 1 (+), 2 (+),
3 (□), 4 (O), 5 (#), 6 (*). 7 (O), 8 (O), and 9 (□). (C) Temperature dependence of 31P chemical
shifts of duplex decamer · [MeCys3, MeCys7]TANDEM (0.8:1) complex. Phosphate positions 1 (X), 2 (X), 3 (O), 4 (+), 5 (#), 6 (*), 7 (O) and 8 (O) and 9 (D).

Drug · Duplex Complex
UV Titration
The decamer · [MeCys3, MeCys7]TANDEM complex was titrated with 0.1 to 0.2 O.D. aliquots of decamer. The titration was monitored by UV spectroscopy either by observing the
overall resulting spectrum after each aliquot addition or by a difference spectrum in which
the initial spectrum was zeroed out and only the changes due to the aliquot additions were
observed. The UV spectrum of the decamer · [MeCys3, MeCys7]TANDEM complex showed
a small change in the spectrum of the drug chromaphore, from which we have calculated
via Scatchard analysis a binding constant, Ka = 4.31 × 104 M–1 (r = 0.86).
HNMR Spectra of the Drug Complex
A TPPI COSY spectrum of the decamer · [MeCys3, MeCys7]TANDEM complex provided
improved resolution and the ability to observe the scalar coupling connectivities of the
1
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peptide backbone in the complex. The cyclic depsipeptide segment of the drug is expected
to be in a beta-sheet conformation from the known X-ray crystal structure of TANDEM.
The beta-sheet structure of the cyclic depsipeptide is also expected from the presence of
the disulfide crosslink which locks the two halves of the cyclic depsipeptide into antiparallel strands. The cyclic depsipeptide should give 1H chemical shifts consistent with a beta
sheet. The chemical shifts in a beta-sheet of the alpha protons are further downfield relative
to the random-coil or alpha-helix. Typical alpha proton chemical shifts of valine, serine,
cysteine, and alanine are centered about 4.5 ppm. The observed chemical shifts from the
TPPI COSY of the decamer-drug complex are centered about 5.15 ppm. These results indicate that the cyclic depsipeptide portion of [MeCys3, MeCys7]TANDEM in the complex is
in a beta-sheet structure. In addition, the alpha to beta proton region of the drug contained
more cross peaks than expected. The proton NMR of the drug alone indicates that the
amino acid residue protons of each Ala, Cys, Val, and Ser residues are degenerate due to
the C2 axis of symmetry. The additional crosspeaks can be assigned to either slowly exchanging multiple conformations of the decamer drug complex or the protons are in magnetically distinct environments based upon the mode of binding. The presence of these
additional crosspeaks suggests that the symmetry of the drug is lost upon binding to the
decamer. However, there is no induced CD when the drug is bound to the decamer indicating that the symmetry of the drug is not disrupted upon binding to the decamer (Powers, unpublished). The lack of an induced CD is consistent with the absence of any drugDNA NOEs and the relatively weak [MeCys3, MeCys7]TANDEM decamer complex binding constant. These results suggest a rapid exchange of the drug between free solution and
a number of possible sites on the duplex.
Molecular Mechanics Energy Minimization Calculation of the Decamer and DecamerTANDEM Complex
As described in the Experimental Section and in more detail below, structures for the decamer duplex and decamer-drug complex were derived from model building and energy
minimization utilizing the AMBER program (51) and NOESY-distance constrained molecular mechanics calculations. The structures derived from these calculations are shown in
figure 14.
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Figure 14. (A) NOESY-distance constrained, energy minimized structure of B-DNA built
duplex decamer, d(CCCGATCGGG)2 complexed with [MeCys3, MeCys7]TANDEM in the
minor groove. The drug · decamer duplex complex was model build and energy minimized. (Stereo view of the drug alone is shown in the inset for clarity.) (B) van der Waals
surface of drug illustrating the fit of the parallel quinoxaline rings fitting into the minor
groove in A.
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Figure 14, continued

Discussion
P Chemical Shifts as a Probe of DNA and DNA Drug Structure
We have noted that 31P chemical shifts can potentially provide a probe of the conformation
of the phosphate ester backbone in nucleic acids and nucleic acid complexes ( 60,64,76–79).
These studies suggested that the 31P resonance of a phosphate diester in a g,g or g–,g– conformation should be several ppm upfield of the 31P signal of an ester in a g,t or t,t conformation (79).
If 31P chemical shifts are sensitive to phosphate ester conformations, they potentially
provide information on two of the most important torsional angles that define the nucleic
acid deoxyribose phosphate backbone. One of these, the C3′-O3′-P-O5′ torsional angle, ζ,
is also found to be the most variable one in the B-form of the double helix and the other
O3′-P-O5′-C5′, α, torsional angle is one of the most variable in the A-form of the duplex (1).
Indeed following the original suggestion of Sundaralingam (80) and based upon recent Xray crystallographic studies of oligonucleotides, Saenger (1) has noted that the P-O bonds
may be considered the “major pivots affecting polynucleotide structure.”
With the recent development of methodologies to assign individual 31P resonances of
oligonucleotides (15,38,39,46,48,57,58,61,63,81) we have been able to begin to understand
some of the factors apparently responsible for 31P chemical shift variations in oligonucleotides (15,38,39,57,69,82–84). As discussed above, one of the major contributing factors that
we have hypothesized determines 31P chemical shifts is the main chain torsional angles of
31
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the individual phosphodiester groups along the oligonucleotide double helix. Phosphates
located toward the middle of a B-DNA double helix assume the lower energy, stereoelectronically (66) favored g–,g– conformation, while phosphodiester linkages located toward
the two ends of the double helix tend to adopt a mixture of g–,g– and t,g– conformations,
where increased flexibility of the helix is more likely to occur. (The notation for the P-O
ester torsion angles follows the convention of Seeman et al. (85) with the ζ, P-O-3′ angle
given first followed by the α, P-O-5′ angle.) Because the g–,g– conformation is responsible
for a more upfield 31P chemical shift, while a t,g– conformation is associated with a lower
field chemical shift, internal phosphates in oligonucleotides would be expected to be upfield of those nearer the ends. Although several exceptions have been observed, this positional relationship appears to be generally valid for oligonucleotides where 31P chemical
shift assignments have been determined (12,15,57,58,60,86).
Eckstein and coworkers (57–59) and our laboratory (12,15,63) have recently suggested
that 31P chemical shifts are also sensitive to sequence-specific structural variations of the
double helix as proposed by Calladine (2) and Dickerson (3). The 31P chemical shifts of
duplex B DNA phosphates correlate reasonably well with some aspects of the Dickerson/Calladine sum function for variation in the helical twist (or helical roll) of the individual base steps in the oligonucleotides. In the B-form DNA double helix with ~10 base pairs
per turn (360°) of the helix each base pair is rotated ca. + 36° (helix twist) with respect to
the nearest neighbor base pair. However, analysis (3) of X-ray crystallographic structures
of a number of duplexes has revealed large variations in local helix structure, with helix
twist varying from 25° to 45°. Correlations between experimentally measured P-O and CO torsional angles and results from molecular mechanics energy minimization calculations
show that these results are consistent with the hypothesis that sequence-specific variations
in 31P chemical shifts are attributable to sequence-specific changes in the deoxyribose phosphate backbone (63).
As shown in figure 4, 31P chemical shifts of the central phosphates 3–8 of the duplex
decamer appear to follow the positional relationship. As would be expected from the phosphate positional relationship, the 31P chemical shifts in the central regions gradually increase (phosphates 3, 4, and 5), reach a maximum at the central phosphate position (5), and
decrease once again for phosphates 6, 7, and 8.
However, in comparison to all other oligonucleotides studied (12,15,57–59,63), the 31P
chemical shifts of the decamer phosphates do not follow any of the predicted sequencespecific variations in either helix twist (R = –0.15) or roll angle (R = 0.38) based upon the
Calladine rules. The CpG phosphate 3 is possibly shifted downfield relative to the expected
value based upon the positional relationship. This is consistent with the expected pyrimidine-purine clash and unwinding at this base step (63). It is quite possible that chemical
exchange of the duplex with other conformers (or even the hairpin loop state) is responsible for this lack of any significant sequence-specific 31P chemical shift variations.
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P NMR of Drug · DNA Complexes
P chemical shifts appear to be generally sensitive to changes in duplex structure resulting
from binding of drugs to the duplex (73,78,82,87). Thus 31P chemical shifts reflect differences in the unwinding angles in both DNA and RNA double helix-drug complexes
(62,73,87,88). Insertion (intercalation) of a drug between the stacked base pairs reduces the
helix twist of the duplex and the resulting decrease in the helix twist is termed the unwinding angle. Numerous mono-intercalating drugs produce an unwinding angle of 10–26°; the
bis-intercalating drugs generally give unwinding angles twice that of the mono-intercalators (1). This unwinding of the DNA helix appears to produce changes in the P-O torsional
angles (ζ, α) from a g–,g– to values such as t,g– (1). Experimentally, downfield shifts on the
order of 1.0 to 2.6 ppm are observed when drugs intercalate into DNA, reflecting these
backbone torsional angle changes (78,82). The phosphorus resonances that shift downfield
have been assigned to the phosphates which bridge the intercalated base pair (38,61).
The 31P NMR spectrum of the decamer · [MeCys3, MeCys7]TANDEM complex is very
similar to that of the decamer alone. There are no large downfield shifts upon addition of
the drug. In fact, there are some modest upfield chemical shifts of a few of the phosphorus
resonances, which is often observed in nonintercalative, groove binding of other drugs to
duplex DNA (69,78). Correlating specific bases to the phosphorus resonance which are affected is not possible since the peaks correspond to degenerate phosphorus signals. These
modest changes in the 31P NMR spectrum of the decamer · [MeCys3, MeCys7]TANDEM
complex thus support a nonspecific, nonintercalation mechanism for the binding of the
drug to the duplex.
31
31

Binding of [MeCys3, MeCys7]TANDEM to Decamer
The footprinting studies of TANDEM and [MeCys3, MeCys7]TANDEM on a 160 base pair
fragment from the E. Coli trp promoter sequence indicated that both drugs protect an average of seven base pairs of DNA (21,41,89). [MeCys3, MeCys7]TANDEM protects only two
sites on the restriction fragment, centered about ApTpT or TpApT. Previous studies on the
quinoxaline antibiotics indicate a bis-intercalation mode of association of the drug (36),
suggesting a similar mechanism for [MeCys3, MeCys7]TANDEM.
The interaction between decamer and [MeCys3, MeCys7]TANDEM was initially established by the ability of the decamer to bring the drug into an aqueous buffer solution. The
solubility of [MeCys3, MeCys7]TANDEM in an aqueous solution is only 6 μM. The decamer
sample was capable of bringing it into solution at millimolar concentrations consistent
with the measured binding constant of [MeCys3, MeCys7]TANDEM for the decamer (Ka =
4.31 × 104 M–1).
The UV spectrum of the decamer · [MeCys3, MeCys7]TANDEM complex provided the
initial indication that the drug was not intercalating into the decamer. The typical effect on
the UV spectrum of an intercalating drug is a shift in the maxima to a longer wavelength
and a decrease in the extinction coefficient (hypochromicity) (26,35). The maxima and extinction coefficient of the [MeCys3, MeCys7]TANDEM drug were perturbed by only a small
degree upon binding to the decamer, suggesting that the decamer does not undergo any
major conformational changes upon drug binding and that binding did not occur by bisintercalation.
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When mono-intercalators and bis-intercalators bind to DNA they induce major changes
in the UV melting curves of DNA The quinoxalines increase the Tm of various DNA polymers by +l.0 to +8.5°C with drug/base pair ratios as low as 0.005 to 0.046 (35,90). The binding of [MeCys3, MeCys7]TANDEM to decamer induces a modest 2.5°C increase in the Tm
of the decamer only at a high drug/base pair ratio of 0.1. This result indicates only a mild
stabilization of the decamer helix implying that intercalation is not the mode of binding.
Structure of the decamer · [MeCys3, MeCys7]TANDEM complex
The lack of major perturbations in the UV, proton, and phosphorus NMR spectra of the
[MeCys3, MeCys7]TANDEM · decamer complex, strongly supports a nonintercalative binding of the drug to the decamer. Because separate NMR resonances are not observed for the
drug complex and the decamer alone, this interaction is fast on the NMR time scale. In
addition, the lack of large site-specific perturbations in the NMR spectra suggest that the
drug undergoes rapid chemical exchange between multiple, nonintercalative binding sites.
While it is not possible to define a unique drug-duplex complex structure, the 31P chemical
shift melting profile (fig. 13B) of the decamer · [MeCys3, MeCys7]TANDEM complex provides some indication of possible regions of the drug-DNA contacts. In contrast to the
overall increase in the UV melting temperature of the complex relative to the duplex alone
of 2.5° (fig. 13A), the presence of the drug results in a decrease in the melting temperature
of three of the phosphorus resonances. Thus the Tm of the phosphate corresponding to the
peak at –4.321 ppm (A5pT6) decreases from 65°C to 50°C, the resonance at –4.199 ppm
(T6C7) decreases from 60°C to 45°C and the resonance at –3.709 ppm (G8pG9) decreases
from 65°C to 55°C. These sites of local destabilization suggest specific regions of contact
between [MeCys3, MeCys7]TANDEM and the decamer sugar phosphate backbone (compare fig. 13B and C).
Additional points of DNA-drug contacts may be inferred from the temperature dependence to the imino spectra and the imino proton chemical shift melting profile (fig. 12).
Analogous to the 31P melting profile, the binding of the drug has decreased the stability of
some of the base pairs as monitored by the Tm of the imino protons. The GC base pairs
were destabilized more than the AT base pair. The melting temperature of the terminal
and internal GC imino protons in the duplex decreases from 30°C to 20°C and from 45°C
to 35°C, respectively in the drug complex. It could be argued that these imino and phosphorus signal effects could be attributable to the residual amount of acetonitrile that remains in solution despite repeated efforts for its removal by relyophilization of the sample.
However, we believe that these selective decreases in the melting temperatures of several
residues as monitored by 1H NMR of the imino protons and 31P NMR of the backbone
phosphates are real effects representing some degree of sequence specificity in the binding
of the drug to the duplex. Note that overall, the melting temperature, as monitored by UV
spectral changes show that the drug stabilizes the duplex form relative to the random coil,
denatured form. Because 1H and 31P NMR are run at 1000-fold higher concentrations than
the UV spectra, and because NMR monitors different melting phenomena, it is not proper
to attempt to directly compare the different measures of melting temperatures.
Additional information establishing some specific interaction of the drug with the second phosphorus from the end comes from the 2D 31P-1H long-range J-resolved spectra (fig.

35

POWERS ET AL., JOURNAL OF BIOMOLECULAR STRUCTURE AND DYNAMICS 7 (1989)

6 and 9). The 31P-H3′ coupling constant of either the phosphorus resonance at –3.709 ppm
(G8pG9) or –3.736(C3pG4) decreases from 5.4 Hz to 2.2 Hz upon addition of [MeCys3,
MeCys7]TANDEM (overlap of the signals prevents definitive assignments). This change in
coupling constant implies a decrease from 175° to 150° in the C4′-C3′-O-P torsional angle.
Molecular Modeling of Decamer Duplex
Using the distances derived from the 2D NOESY spectrum of figure 10, in conjunction with
restrained molecular mechanics and dynamics calculations, we derived a structure for the
duplex decamer. Distances were calculated by integrating the crosspeaks and utilizing the
two-spin approximation at short mixing times (71). Although volumes were measured for
a complete set of mixing times (50, 100, 200, 300, 400, 500, and 700 ms) the volumes for a
single 200 ms TPPI NOESY were used to measure the intra and inter proton distances from
the observed NOE crosspeaks (table III).
The NOESY buildup curves (data not shown) demonstrated that the NOEs were primary NOEs not appreciably affected by spin diffusion. (A complete relaxation matrix calculation analysis of the NOESY buildup curves has confirmed that the qualitative features
of the structures described are essentially correct. A comparison of the structures derived
from both the two-spin approximation at various mixing times and a complete relaxation
matrix (91) approach will be described in Meadows et al., in preparation.) Starting from an
idealized model-built duplex structure, we have used NOESY-derived distances to constrain the molecular mechanics/dynamics energy minimization program AMBER (51) to
minimize the energy of the decamer duplex. Instead of a simple harmonic potential error
function to restrain the NMR-derived distances, we have modified AMBER so as to provide a flat well harmonic function which better reflects the intrinsic accuracy of these NOESY distance restraints (62,92). We have generally used an estimated error of ± 15% in the
NOESY distances.
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Table III. NOE Distances Derived from 200 msec NOESY Spectrum of Duplex
Intranucleotide Distances (Rij)a
Base

H6/H8 to H1′

H6/H8 to H2′

H6/H8 to H2″

H6/H8 to H3′

H1′ to H2′

H1′ to H2″

C1

—

—

—

—

2.51

2.18

H1′ to H3′

—

C2

2.80

2.23

2.58

—

2.63

2.37

2.55

C3

3.26

2.53

2.61

—

2.64

2.41

—

G4

2.77

2.20

2.31

2.79

2.52

2.45

2.66

A5

3.25

2.65

2.74

2.83

2.68

2.57

3.25

T6

3.34

2.75

2.86

—

2.61

2.36

—

C7

—

2.63

2.76

—

2.64

2.39

—

G8

2.86

—

—

3.19

—

—

2.76

G9

—

2.54

—

—

2.25

2.22

—

G10

3.18

—

—

—

2.46

2.27

—

Internucleotide Distances (Ri,j–1)a
Base

H6/H8 to H1′

H6/H8 to H2′

H6/H8 to H2″

C1

—

—

—

C2

—

—

—

C3

3.20

—

2.91

G4

3.20

3.35

2.74

A5

2.75

3.26

2.79

T6

3.26

3.44

2.88

C7

3.28

—

—

G8

3.28

3.36

2.48

G9

2.75

—

—

G10

—

—

—

a. All distances referenced to C7 (H5/H6) crosspeak, assuming a reference distance of 2.45 angstroms.

While some differences are observed between the constrained and unconstrained minimized duplexes (particularly at the ends of the duplex where fraying of the strands is
possible), the main features of the B-DNA duplex are retained in both the dynamics and
mechanics calculations.
Molecular Modeling of [MeCys3, MeCys7]TANDEM · Duplex Complex
The results from the imino proton chemical shift melting curve, 31P melting curve and the
2D 31P-1H long-range J-resolved spectrum of the drug duplex complex indicate possible
points of contact between the drug and the second and fifth phosphate along the DNA
backbone. The AMBER program was used to calculate an energy minimized structure for
the decamer · [MeCys3, MeCys7]TANDEM complex. Thus the initial decamer part of the
drug complex structure was based upon the distances derived from the free duplex NOESY spectra and the distance-constrained, minimized structure. The binding of the
[MeCys3, MeCys7]TANDEM to the decamer resulted in significant increases in the 1H NMR
linewidths. A significant amount of resolution enhancement was required to analyze the
decamer · drug complex NOESY spectrum, which precludes accurate integration of the
NOESY crosspeak volumes. However, as shown in figure 11A/B, the drug complex spectra
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are qualitatively similar to the duplex spectra (fig. l0A/B), indicating little overall perturbation in the B-DNA geometry. An energy-minimized structure of [MeCys3, MeCys7]TANDEM, based upon the X-ray structure of TANDEM, was docked onto the decamer using
the molecular modeling program MIDAS. The [MeCys3, MeCys7]TANDEM drug was positioned at one end of the decamer in the minor. Although the crystal structure of the Triostin A · d(CGTACG)2 complex shows that the cyclic peptide linking the bis-intercalated
quinoxaline rings binds in the minor groove, the quinoxaline heterocycles of these drugs
are physically too large to fit into the minor groove without intercalation or rotation about
the serine-quinoxaline bonds. However, simple rotation about the serine-quinoxaline
C(O)-aromatic ring bonds moves the quinoxaline rings from a self-stacking conformation
to a coplanar orientation which allows the quinoxaline rings to easily insert deeply into the
minor groove (fig. 14A/B). In the minor-groove structure, only the two quinoxaline rings
can be easily inserted deep within the groove without major deformation of the duplex
structure (fig. 14B). The walls of the minor groove are quite hydrophobic and the tight fit
of the aromatic chromophores provides a significant amount of the interaction energy between the drug and duplex. The side chain of the two valines also approaches just to the
van der Waals radii of the hydrophobic side of the sugar residues, providing further stabilization of the complex. Note that the depsipeptide is on the outside of the groove.
Most interestingly, this minor-groove binding geometry places the nonintercalating
quinoxaline rings at an ca. 45° angle relative to the stacked base pairs. It appears quite
reasonable to envision a process whereby the quinoxaline ring rotates so that the chromophore is now co-planar to the base-pairs (requiring some opening also of the minor
groove), and with unwinding of the duplex the chromophore can now easily intercalate
between the stacked base pairs. This would be the mono-intercalated geometry and further
twisting and intercalation of the other quinoxaline ring, followed by the depsipeptide ring
settling into the widened minor groove would complete the bis-intercalation process. We
therefore suggest that the minor-groove structure could represent the initial encounter
complex with the DNA, not only for the bis-intercalators but possibly as well for monointercalators such as Actinomycin D.
Groove Binding vs. Bis-lntercalation
Because we do not observe any drug to duplex NOE crosspeaks, the drug must bind in a
nonspecific mode. All of our observations point to a nonintercalative mode of association
of the [MeCys3, MeCys7]TANDEM to the duplex decamer. However, previous studies have
suggested that this drug, and others related to it, binds to DNA via a mixture of monointercalation and bis-intercalation with multiple binding sites. Nonspecific surface (or
groove) binding have been postulated only as an intermediate in the exchange between
different binding modes and binding sites. The primary factors that influence the ability of
the quinoxaline and related drugs to bis-intercalate are the nature of the linker between
the chromophores as well as the DNA sequence. A minimum length of 10 Å is required to
allow the two chromophores to bis-intercalate about a “sandwiched” base pair so as not to
violate the nearest-neighbor exclusion principle. A stiff linker is also required to prevent
self-stacking of the chromophores in an aqueous environment (20,21). Self-stacking has
been observed for some of these bis-intercalators (23).
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The [MeCys3, MeCys7]TANDEM meets all of the criteria required for a good bis-intercalator. The quinoxaline class of antitumor drugs have been shown to be bis-intercalators
(17,25–27,35). This includes the quinomycin drug echinomycin and the triostin drugs—
triostin A and its derivative TANDEM. Based upon proton NMR and X-ray crystallography the various quinoxaline drugs have the same basic C-shaped structure with the
quinoxaline rings planar to each other and perpendicular to the rectangular shaped cyclic
depsipeptide (28–30,31).
The heterogeneity in the binding modes has also been monitored by the effect of the
binding constants under varied conditions. The bis-intercalators show a dramatic increase
in DNA affinity and binding constants relative to mono-intercalators. Mono-intercalators
have binding constants on the order of 105 M–1; binding constants are affected by drug
concentration, ionic strength, and temperature. As the concentration of drug to duplex is
increased, all the bis-intercalators experience an increase in the relative amount of bis-intercalation and a decrease in the amount of mono-intercalation and nonspecific binding.
The points of these transitions are drug dependent but usually occur at an r value (defined
as the ratio of drug bound to DNA base pairs) of 0.2 for bis-intercalation and an r value of
0.l for mono-intercalation (18,20). The bis-intercalators stabilize the DNA to a greater extent (higher Tm) in a solution of low ionic strength, which implies a higher percentage of
bis-intercalation. Higher temperature favors mono-intercalation over bis-intercalation,
which implies that bis-intercalation is driven by the thermodynamics of chromophore
stacking and mono-intercalation is driven by the properties of the depsipeptide-DNA interaction (93).
Ethidium bromide, a known intercalator, has been shown to have a secondary electrostatic binding site. This secondary binding site has a lower ligand binding affinity but can
be populated at the expense of the primary binding mode. Competition between the primary and secondary binding sites is salt and buffer dependent. At high free-ligand concentration, the secondary binding site is the predominate mode of binding. The postulation
of an intermediate nonspecific type of binding is supported by some of the work done with
bis-intercalator derivatives. Some of these derivatives have linkers which are too short to
allow for bis-intercalation or are methylated in a fashion to sterically hinder intercalation,
resulting in compounds which are mono-intercalators or nonintercalators.
DNA binding constants for triostin A and TANDEM are on the order of 10 6 M–1 and 104
–1
M , respectively. The binding constants for the three quinoxaline drugs are dependent on
the nature of the bound DNA. Both echinomycin and triostin A show a higher preference
for DNA rich in GC, triostin greater than echinomycin. Gao and Patel (24) have shown that
echinomycin appears to insert the quinoxaline rings between the A1-C2 and G3-T4 base
steps in d (ACGT)2, consistent with this specificity. However, TANDEM has a binding constant 1500 times greater when bound to AT-rich regions as compared to GC-rich regions.
The [MeCys3, MeCys7]TANDEM also shows a binding site preference centered around
ATA or TAT regions. The smaller binding constant to d(CCCGATCGGG)(Ka = 4.31 × 104
M–1) is consistent with nonintercalative binding, and thus the AT base step in our sequence
apparently does not provide an effective enough bis-intercalation site for binding the
(MeCys3, MeCys7]TANDEM.
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Conclusion
All of the evidence provided here support binding of the (MeCys3, MeCys7]TANDEM to a
small DNA fragment possessing the correct specificity in a nonspecific minor groove binding mode. All previous evidence regarding these quinoxaline drugs such as [MeCys3,
MeCys7]TANDEM has shown that the major interaction with DNA is either bis-intercalation or mono-intercalation. Most DNA-binding drugs that bind in a nonintercalative mode
associate with the DNA through the narrow, minor groove and are significantly stabilized
by hydrophobic interactions between the drug and the walls and floor of the minor groove
(cf. netropsin and distamycin; 94,95). Although our model for the structure of the [MeCys3,
MeCys7]TANDEM · decamer complex (fig. 14) is speculative and based largely upon the
few 1H and 31P NMR perturbations induced by the drug, as well as model building and
AMBER energy minimization, it represents a structure that, to our knowledge, is quite
novel. In drugs such as netropsin and distamycin, the “thin edge” of the molecules
(roughly the 3.4 Å thickness of an aromatic ring) appear to possess the appropriate crescent
shape and dimensions to nicely insert into the helical narrow minor groove of the duplex
(which varies from ca. 4–6 Å; 94,95). This fit of the natural crescent shape of the these drugs
to the natural curvature of the DNA is probably at least partially responsible for their tight
binding and sequence specificity (hence the preference for many of these drugs for the
narrower minor groove in AT-rich regions of DNA). We have shown that the quinoxaline
“bis-intercalators” are relatively constrained by the depsipeptide linkage so that the Cshape of the tethered quinoxaline rings prevents the thin edge of the drug from conveniently fitting into the minor groove without significant distortion of the drug. Perhaps as
described in our model only the quinoxaline chromophores are deeply bound within the
minor groove. This may represent the initial association complex which then is capable of
forming the ultimate bis-intercalation complex in those sequences providing the appropriate interactions with the depsipeptide moiety.
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